When was EpiVax founded?

EpiVax was founded in 1998 and raised its 1st funding round within a year of its incorporation.

Where is EpiVax located?

EpiVax is headquartered in Providence, United States.

Who is the current CEO of EpiVax?

Anne S De Groot of EpiVax. They have also founded 1 company.

How many employees does EpiVax have?

As of Jul 31, 2026, the latest employee count at EpiVax is 52.

Is EpiVax a funded company?

EpiVax is a funded company, having raised a total of $795K across 33 funding rounds to date. The company's 1st funding round was a $***** Unattributed round, raised on 1998.

When was the latest funding round of EpiVax?

EpiVax's latest funding was a $***** Grant (prize money) round on Feb 05, 2025, with participation from 1 investor.

Where does EpiVax rank among its competitors?

EpiVax ranks 18th amongst 421 active competitors, of which 140 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was DBV Technologies, which secured $307M in Apr, 2025.

Who are the top competitors of EpiVax?

EpiVax's top competitors include BeiGene, Biogen and argenx. Among them, DBV Technologies secured the most recent funding round in April, 2025.

EpiVax - 2026 Company Profile, Team, Funding & Competitors

Company Details

Immunoinformatics modeling and gene sequencing for vaccines and drugs. The company offers a T cell epitope-driven vaccine for covid-19, a biodefense vaccine for smallpox, tularemia, TB, pylori, and influenza, The vaccines are developed by editing protein sequences using proprietary immuno-informatics tool called tregitope and de-immunization.

Website: epivax.com
Social

Key Metrics

Founded Year

1998

Location

Providence, United States

Stage

Acquired

Total Funding

$795K in 33 rounds

Latest Funding Round

Grant (prize money), Feb 05, 2025, $*****

Investors

FDA & 5 more

Ranked

18^th among 421 active competitors

Employee Count

52 as on Jul 31, 2026

Similar Companies

BeiGene & 491 more

Exit Details

Acquired by SV Health Investors (Apr 02, 2026)

View EpiVax's full profile

EpiVax got acquired by SV Health Investors on Apr 02, 2026.

Click here to take a look at EpiVax's acquisition in detail

EpiVax has raised a total funding of $795K over 33 rounds. Its first funding round was on 1998. Its latest funding round was a Grant (prize money) round on Feb 05, 2025 for $*****. 1 investor participated in its latest round. EpiVax has 6 institutional investors.

Here is the list of recent funding rounds of EpiVax:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 05, 2025	8543437	Grant (prize money)	7563043	7275070	1419021	9860452
Sep 30, 2023	9421028	Grant (prize money)	1287127	4068724	8083678	HHS
Aug 01, 2023	4148702	Grant (prize money)	4771790	9201613	8375681	HHS

Access funding benchmarks and valuations. Sign up today!

View details of EpiVax's funding rounds and investors

The founders of EpiVax is Anne S De Groot. Anne S De Groot is the CEO of EpiVax.

Here are the details of EpiVax's key team members:

Anne S De Groot: Founder & CEO of EpiVax and founder of 1 other company.
Contact Info: 1 email address

View details of EpiVax's Founder profiles and Board Members

EpiVax's employee count trend

EpiVax has 52 employees as of Jul 26. Here is EpiVax's employee count trend over the years:

Uncover EpiVax's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of EpiVax include BeiGene, Biogen and argenx. Here is the list of Top 10 competitors of EpiVax, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
4th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
5th	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	71/100
6th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	69/100
7th	Immunocore 2008, Abingdon (United Kingdom), Public	Developer of bispecific T cell receptor therapies for human diseases	$601M	General Atlantic, BlackRock & 50 others	69/100
8th	ADMA Biologics 2005, Ramsey (United States), Public	Biopharmaceutical company innovating plasma-derived therapeutics for immune deficiencies and infectious diseases	$17.6M	Aisling Capital, Burrill and Company & 4 others	68/100
9th	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100
10th	DBV Technologies 2002, Bagneux (France), Public	Developer of products for the treatment of various kinds of food allergies	$68.9M	Sofinnova Partners, Lundbeck Foundation & 16 others	68/100
18th	EpiVax 1998, Providence (United States), Acquired	Immunoinformatics modeling and gene sequencing for vaccines and drugs	$795K	FDA, Slater Technology Fund & 4 others	66/100